These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 1322690

  • 21. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
    Flavell DJ, Cooper S, Okayama K, Emery L, Flavell SU.
    Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins.
    Bolognesi A, Polito L, Tazzari PL, Lemoli RM, Lubelli C, Fogli M, Boon L, de Boer M, Stirpe F.
    Br J Haematol; 2000 Aug; 110(2):351-61. PubMed ID: 10971392
    [Abstract] [Full Text] [Related]

  • 25. Anti-CD30 immunotoxins with native and recombinant dianthin 30.
    Bolognesi A, Tazzari PL, Legname G, Olivieri F, Modena D, Conte R, Stirpe F.
    Cancer Immunol Immunother; 1995 Feb; 40(2):109-14. PubMed ID: 7882380
    [Abstract] [Full Text] [Related]

  • 26. Hepatoxicity of ricin, saporin or a saporin immunotoxin: xanthine oxidase activity in rat liver and blood serum.
    Battelli MG, Buonamici L, Polito L, Bolognesi A, Stirpe F.
    Virchows Arch; 1996 Feb; 427(5):529-35. PubMed ID: 8624583
    [Abstract] [Full Text] [Related]

  • 27. Experimental therapy in Hodgkin's disease.
    Engert A, Pohl C, Diehl V.
    Ann Oncol; 1992 Sep; 3 Suppl 4():97-100. PubMed ID: 1333274
    [Abstract] [Full Text] [Related]

  • 28. Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells.
    Bregni M, Lappi DA, Siena S, Formosa A, Villa S, Soria M, Bonadonna G, Gianni AM.
    J Natl Cancer Inst; 1988 Jun 01; 80(7):511-7. PubMed ID: 3259267
    [Abstract] [Full Text] [Related]

  • 29. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model.
    Tazzari PL, Polito L, Bolognesi A, Pistillo MP, Capanni P, Palmisano GL, Lemoli RM, Curti A, Biancone L, Camussi G, Conte R, Ferrara GB, Stirpe F.
    J Immunol; 2001 Oct 15; 167(8):4222-9. PubMed ID: 11591743
    [Abstract] [Full Text] [Related]

  • 30. A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies.
    Bolognesi A, Tazzari PL, Tassi C, Gromo G, Gobbi M, Stirpe F.
    Clin Exp Immunol; 1992 Sep 15; 89(3):341-6. PubMed ID: 1516253
    [Abstract] [Full Text] [Related]

  • 31. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
    Ferrini S, Sforzini S, Canevari S.
    Methods Mol Biol; 2001 Sep 15; 166():177-92. PubMed ID: 11217367
    [No Abstract] [Full Text] [Related]

  • 32. Hodgkin's disease. Future treatment strategies: fact or fiction?
    Schnell R, Barth S, Diehl V, Engert A.
    Baillieres Clin Haematol; 1996 Sep 15; 9(3):573-93. PubMed ID: 8922247
    [Abstract] [Full Text] [Related]

  • 33. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A.
    Clin Cancer Res; 2002 Jun 15; 8(6):1779-86. PubMed ID: 12060617
    [Abstract] [Full Text] [Related]

  • 34. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence.
    Falini B, Flenghi L, Fedeli L, Broe MK, Bonino C, Stein H, Dürkop H, Bigerna B, Barbabietola G, Venturi S.
    Br J Haematol; 1992 Sep 15; 82(1):38-45. PubMed ID: 1329918
    [Abstract] [Full Text] [Related]

  • 35. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.
    French RR, Bell AJ, Hamblin TJ, Tutt AL, Glennie MJ.
    Leuk Res; 1996 Jul 15; 20(7):607-17. PubMed ID: 8795695
    [Abstract] [Full Text] [Related]

  • 36. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
    Pohl C, Renner C, Schwonzen M, Schobert I, Liebenberg V, Jung W, Wolf J, Pfreundschuh M, Diehl V.
    Int J Cancer; 1993 May 28; 54(3):418-25. PubMed ID: 8389737
    [Abstract] [Full Text] [Related]

  • 37. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU.
    Int J Cancer; 1995 Jul 28; 62(3):337-44. PubMed ID: 7543082
    [Abstract] [Full Text] [Related]

  • 38. Different sensitivity of CD30+ cell lines to Ber-H2/saporin-S6 immunotoxin.
    Battelli MG, Bolognesi A, Olivieri F, Polito L, Stirpe F.
    J Drug Target; 1998 Jul 28; 5(3):181-91. PubMed ID: 9606008
    [Abstract] [Full Text] [Related]

  • 39. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 May 01; 79(9):2201-14. PubMed ID: 1373967
    [Abstract] [Full Text] [Related]

  • 40. Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM).
    Barbieri L, Dinota A, Gobbi M, Tazzari PL, Rizzi S, Bontadini A, Lemoli RM, Tura S, Stirpe F.
    Eur J Haematol; 1989 Mar 01; 42(3):238-45. PubMed ID: 2784390
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.